TY  - GEN
AU  - Pönisch,Wolfram
AU  - Heyn,Simone
AU  - Beck,Juliane
AU  - Wagner,Ina
AU  - Mohren,Martin
AU  - Hoffmann,Franz A
AU  - Lange,Thoralf
AU  - Schmalfeld,Marion
AU  - Zehrfeld,Thomas
AU  - Schwarzer,Andreas
AU  - Winkelmann,Cornelia
AU  - Edelmann,Thomas
AU  - Röhrborn,Ramona
AU  - Hebenstreit,Karin
AU  - Al-Ali,Haifa K
AU  - Jäkel,Nadja
AU  - Niederwieser,Dietger
TI  - Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077
SN  - 1365-2141
PY  - 2014///0204
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - Bendamustine Hydrochloride
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - Female
KW  - Humans
KW  - Lenalidomide
KW  - Male
KW  - Middle Aged
KW  - Multiple Myeloma
KW  - drug therapy
KW  - Nitrogen Mustard Compounds
KW  - administration & dosage
KW  - Prednisolone
KW  - Recurrence
KW  - Thalidomide
N1  - Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1111/bjh.12361
ER  -